Compare AFLAC Incorporated (AFL) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs BioNano Genomics Inc — how do they compare? AFLAC Incorporated trades at $120.89 (market cap $60.70B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: AFLAC Incorporated is far larger — about 4443.6× BioNano Genomics Inc's market cap, and AFLAC Incorporated pays a 2.02% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| AFL | BNGO | |
|---|---|---|
Market Cap | $60.70B | $13.66M |
Sector | Financials | Health |
52-Week High | $129.55 | $4.92 |
52-Week Low | $103.55 | $1.06 |
Enterprise Value | $70.65B | $16.26M |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFL trades at $121.09, down 0.7% on the day, with a bullish overall technical signal but bearish moving averages and oscillators. The stock shows strong profitability with a 26.59% net income margin and 16.91% ROE, though recent quarters have seen EPS misses. Revenue declined to $17.36B in 2025, with net income of $3.65B. Recent news highlights AFL's rebranding of network services and ongoing dividend commitments.
Outlook is mixed; solid fundamentals and a 43-year dividend growth history support income investors, but near-term headwinds include revenue pressure in Japan and FX impacts. Analyst consensus is cautious with a $118 price target below current levels, suggesting limited upside amid execution risks and competitive pressures.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
